Our markets

Allergy Therapeutics continues to maintain a strong presence in Europe with established operations in 19 markets, either directly or via partnerships.

Germany remains the Group’s main market, generating approximately 53% of the Group’s revenue in the 6 months ending 31 December 2023.

In markets where we do not have a direct presence, we often make out products available through partners. The most important distributor markets for the Group are Canada, the Czech and Slovak Republics, South Korea and Greece.